Financière de Tubize S.A. Financière de Tubize S.A.

Financière de Tubize S.A.

TUB

Rank in Stocks #2218
Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a... Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a global biopharmaceutical firm, primarily through its investment in UCB. The company is dedicated to discovering and advancing innovative medicines and solutions focused on neurological and immunological disorders. Its current commercial offerings include Cimzia, an established treatment for a range of inflammatory conditions such as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For partial-onset seizures in epilepsy, it provides Briviact, Vimpat, and Keppra, alongside Nayzilam, a nasal spray. Neupro addresses Parkinson's disease and restless legs syndrome. Additionally, the portfolio features Evenity, an injectable therapy for osteoporosis, and Bimzelx, used to manage moderate to severe plaque psoriasis. The company's development pipeline highlights several promising candidates: Staccato, aimed at stereotypical prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Other therapies under investigation include bimekizumab, which targets psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab, for conditions like myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol, intended for systemic lupus erythematosus.
Share Price
$205.44
Market Cap
$9.14B
Change (1 day)
0.23%
Change (1 year)
-23.56%
Country
BE
Trade Financière de Tubize S.A. (TUB)

Category

Healthcare
Operating Margin for Financière de Tubize S.A. (TUB)
Operating Margin as of October 2026 TTM: 0.00%
According to Financière de Tubize S.A. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2023 the company had an Operating Margin of 0.00%.
Operating Margin history for Financière de Tubize S.A. from 2003 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) 0.00% -100.00%
2024 -16,866.37% 0.00%
2023 0.00% -100.00%
2022 -22,362.69% 0.00%
2021 0.00% 0.00%
2020 0.00% -100.00%
2019 -28,000.00% 0.00%
2018 0.00% 0.00%
2017 0.00% -100.00%
2016 -224.17% -99.62%
2015 -59,400.00% 0.00%
2014 0.00% 0.00%
2013 0.00% 0.00%
2012 0.00% 0.00%
2011 0.00% 0.00%
2010 0.00% 0.00%
2009 0.00% 0.00%
2008 0.00% 0.00%
2007 0.00% 0.00%
2006 0.00% 0.00%
2005 0.00% -100.00%
2004 14,700.00% 0.00%
2003 0.00% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
38.59% -
US
-149.01% -
US
25.57% -
AU
0.00% -
CH
28.81% -
NL
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.